As emerging AD therapeutics often target amyloid and tau, levels of established CSF AD biomarkers (Aβ42, t-Tau, and p-Tau181) may serve better to inform target engagement than treatment-associated downstream effects. Here, MAPT is linked to Alzheimer disease.